CRL Charles River Laboratories International Inc

Price (delayed)

$217.99

Market cap

$11.07B

P/E Ratio

26.01

Dividend/share

N/A

EPS

$8.38

Enterprise value

$13.78B

Charles River Laboratories, Inc., is an American corporation specializing in a variety of preclinical and clinical laboratory services for the pharmaceutical, medical device and biotechnology industries. It also supplies assorted ...

Highlights
The price to earnings (P/E) is 44% lower than the last 4 quarters average of 46.3 and 27% lower than the 5-year quarterly average of 35.7
Charles River Laboratories International's gross profit has increased by 21% YoY and by 2.1% QoQ
The quick ratio has declined by 29% year-on-year but it is up by 10% since the previous quarter
Charles River Laboratories International's debt has increased by 24% YoY

Key stats

What are the main financial stats of CRL
Market
Shares outstanding
50.8M
Market cap
$11.07B
Enterprise value
$13.78B
Valuations
Price to earnings (P/E)
26.01
Price to book (P/B)
4.22
Price to sales (P/S)
3.04
EV/EBIT
24.12
EV/EBITDA
16.2
EV/Sales
3.8
Earnings
Revenue
$3.63B
EBIT
$571.23M
EBITDA
$850.56M
Free cash flow
$411.99M
Per share
EPS
$8.38
Free cash flow per share
$8.14
Book value per share
$51.7
Revenue per share
$71.67
TBVPS
$66.34
Balance sheet
Total assets
$7.08B
Total liabilities
$4.4B
Debt
$2.94B
Equity
$2.61B
Working capital
$339.25M
Liquidity
Debt to equity
1.13
Current ratio
1.34
Quick ratio
0.95
Net debt/EBITDA
3.18
Margins
EBITDA margin
23.4%
Gross margin
37.6%
Net margin
11.6%
Operating margin
16.9%
Efficiency
Return on assets
6.1%
Return on equity
17.1%
Return on invested capital
11.4%
Return on capital employed
9.4%
Return on sales
15.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CRL stock price

How has the Charles River Laboratories International stock price performed over time
Intraday
0.23%
1 week
3.89%
1 month
-10.81%
1 year
-41.35%
YTD
-42.14%
QTD
-23.23%

Financial performance

How have Charles River Laboratories International's revenue and profit performed over time
Revenue
$3.63B
Gross profit
$1.36B
Operating income
$614.94M
Net income
$422.47M
Gross margin
37.6%
Net margin
11.6%
CRL's operating income is up by 33% YoY and by 4.3% QoQ
Charles River Laboratories International's gross profit has increased by 21% YoY and by 2.1% QoQ
CRL's revenue is up by 19% year-on-year and by 2.5% since the previous quarter
The net income has increased by 13% year-on-year and by 8% since the previous quarter

Growth

What is Charles River Laboratories International's growth rate over time

Valuation

What is Charles River Laboratories International stock price valuation
P/E
26.01
P/B
4.22
P/S
3.04
EV/EBIT
24.12
EV/EBITDA
16.2
EV/Sales
3.8
The price to earnings (P/E) is 44% lower than the last 4 quarters average of 46.3 and 27% lower than the 5-year quarterly average of 35.7
The EPS rose by 11% YoY and by 8% QoQ
The price to book (P/B) is 45% lower than the last 4 quarters average of 7.6 and 22% lower than the 5-year quarterly average of 5.4
The equity is up by 20% year-on-year and by 3% since the previous quarter
The P/S is 44% lower than the last 4 quarters average of 5.4 and 13% lower than the 5-year quarterly average of 3.5
CRL's revenue is up by 19% year-on-year and by 2.5% since the previous quarter

Efficiency

How efficient is Charles River Laboratories International business performance
The company's return on invested capital fell by 18% YoY
The ROS fell by 14% YoY
The company's return on assets fell by 12% YoY but it rose by 3.4% QoQ
The ROE has contracted by 10% YoY but it has grown by 3.6% from the previous quarter

Dividends

What is CRL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CRL.

Financial health

How did Charles River Laboratories International financials performed over time
The company's total assets is 61% higher than its total liabilities
The quick ratio has declined by 29% year-on-year but it is up by 10% since the previous quarter
Charles River Laboratories International's current ratio has decreased by 24% YoY but it has increased by 9% from the previous quarter
Charles River Laboratories International's debt is 13% higher than its equity
Charles River Laboratories International's debt has increased by 24% YoY
The equity is up by 20% year-on-year and by 3% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.